These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10457421)

  • 21. Multiple myeloma: an update of developments in targeted therapy.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):379-89. PubMed ID: 15877532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide.
    Srinivasan S; Schiffer CA
    Leuk Res; 2009 Apr; 33(4):561-4. PubMed ID: 18676017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pamidronate and 1,24(S)-dihydroxyvitamin D2 synergistically inhibit the growth of myeloma, breast and prostate cancer cells.
    Wigington DP; Strugnell SA; Knutson JC
    Anticancer Res; 2005; 25(3B):1909-17. PubMed ID: 16158925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hemocytological classification, clinical staging and polychemotherapy of multiple myeloma].
    István L; Karl W; Michael H; Günter A; Kelényi G; Várbíró M; Dieter R
    Orv Hetil; 1983 Feb; 124(6):313-9. PubMed ID: 6835675
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical observation on effect of combined therapy of pamidronati sodium and shenfu injection in treating multiple myeloma caused ostealgia].
    Ma M
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Jan; 24(1):67-8. PubMed ID: 14976895
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of multiple myeloma].
    Harousseau JL
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1649-55. PubMed ID: 11103435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of bisphosphonates in multiple myeloma.
    Kyle RA
    Ann Intern Med; 2000 May; 132(9):734-6. PubMed ID: 10787368
    [No Abstract]   [Full Text] [Related]  

  • 29. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
    Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M
    Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of effective new treatments for multiple myeloma.
    Anderson KC; Pazdur R; Farrell AT
    J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel strategies in the treatment of relapsed/refractory multiple myeloma. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2003 Aug; 17(8):1063-5. PubMed ID: 12966673
    [No Abstract]   [Full Text] [Related]  

  • 32. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 33. Update in hematology.
    Goodnight SH; Feinstein DI
    Ann Intern Med; 1998 Apr; 128(7):545-51. PubMed ID: 9518399
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-tumor activity of pamidronate in human multiple myeloma.
    Kondo H; Mori A
    Leuk Lymphoma; 2002 Apr; 43(4):919-21. PubMed ID: 12153188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma.
    Desikan R; Veksler Y; Raza S; Stokes B; Sabir T; Li ZJ; Jagannath S
    Br J Haematol; 2002 Nov; 119(2):496-9. PubMed ID: 12406092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chlorozotocin: phase II evaluation in patients with myeloma.
    Cornell CJ; Pajak TF; McIntyre OR
    Cancer Treat Rep; 1984 Apr; 68(4):685-6. PubMed ID: 6231990
    [No Abstract]   [Full Text] [Related]  

  • 38. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
    Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
    Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Secondary malignant neoplasms and cytostatic therapy].
    Gerhartz D
    Lebensversicher Med; 1982 Jun; 34(5):110-3. PubMed ID: 6125858
    [No Abstract]   [Full Text] [Related]  

  • 40. [The complications during the therapy for multiple myeloma].
    Spicka I
    Vnitr Lek; 2006 Feb; 52(2):115. PubMed ID: 16623271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.